Teva Stock Soars After Reaching $4.25 Billion Opioid Settlement | Barron's
Generic-drug stocks slammed by report of expanded price-fixing probe - MarketWatch
Teva Stock Has Crumbled, and Chairman Sol Barer Is Buying Up Shares | Barron's
Perrigo rejects Mylan, opening door for Teva - MarketWatch
Teva Pharmaceutical CEO Talks Opioids, Lawsuits, and the Long Road Ahead | Barron's
Declining sales of blockbuster drug drag Teva revenue lower - MarketWatch
Teva to lay off 14,000 workers in bid for survival — but some are skeptical - MarketWatch
Teva's generic EpiPen approved in the U.S., with perfect timing - MarketWatch
Teva Pharmaceuticals (@TevaUSA) / Twitter
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Drugmaker Teva Pharmaceuticals found guilty for contribution to opioid crisis - MarketWatch
MarketWatch on Twitter: "Teva Pharmaceutical named Kare Schultz as its new chief executive https://t.co/pyLR2vL5Ep https://t.co/pD8godrT5C" / Twitter
Drug maker Teva's U.S. unit indicted on price-fixing charges - MarketWatch
Teva's Earnings and Outlook Miss Estimates. Currency Moves Are to Blame. | Barron's
Mylan sees opportunity in rival Teva's weakness - MarketWatch
Well, well,we'll...said he didn't know why “his team” invested which lowered the stock for months then just doubled his… | Dow jones companies, Investing, Dow jones
Teva stock drops 10% as generics turnaround looks uncertain - MarketWatch
Teva Pharmaceutical Names Richard Francis as CEO, President - WSJ
FDA approves first rival generic EpiPen, sending Teva shares up 6% - MarketWatch
Teva shares surge on corporate shake-up - MarketWatch
Teva Pharmaceuticals (@TevaUSA) / Twitter
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Teva to acquire Mexico's Rimsa for $2.3 billion - MarketWatch
